BCM
PVLA

BlueCrest Capital Management’s Palvella Therapeutics PVLA Stock Holding History

BlueCrest Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.49M Buy
+20,000
New +$2.09M 0.15% 129

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlueCrest Capital Management's PVLA Position: Q1 2026 in Review

BlueCrest Capital Management opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 20,000 shares worth $2.49M. The stake represents 0.15% of the portfolio and ranks #129 among its holdings.

180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • BlueCrest Capital Management held 20,000 shares of Palvella Therapeutics worth $2.49M as of Q1 2026.
  • Palvella Therapeutics was a new BlueCrest Capital Management position in Q1 2026.
  • Palvella Therapeutics made up 0.15% of BlueCrest Capital Management's portfolio in Q1 2026, its #129 holding.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on BlueCrest Capital Management's 13F filing for Q1 2026, filed 15 May 2026.